Across TCGA pan-cancer cohorts, ACSL5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACSL5 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ACSL5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ACSL5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, PRAD, and CHOL are the cancer types where ACSL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.628	.018	14	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →
SKCM	DFS	Median	III,IV	0.241	0.664	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ACSL5 tumor-vs-normal RNA expression · all ACSL5 data types